Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECC0509 DDI Trial in Healthy Adults
NCT07873229Phase 1Not yet recruiting
- Sponsor
- Eccogene
- Start
- Nov 2026
- Primary completion
- Mar 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of ECC0509 in Nonalcoholic steatohepatitis (NASH) and osteoarthritis (OA) (2 cohorts), sponsored by Eccogene. Primary endpoints: Maximum plasma concentration, Time to maximum plasma concentration and 2 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
ECC0509
03
Conditions
Nonalcoholic steatohepatitis (NASH)osteoarthritis (OA)
Beyond the preview
Go deeper on NCT07873229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07873229.